Fig. 3.

CD4+ and CD8+ T lymphocytes do not show in vivo proliferation during ZA and IL-2 therapy in RCC patients, while Vγ9 Vδ2 T lymphocytes show minimal expansion in Cohort A. a PBMC collected from patients in Cohort A before and after ZA and IL-2 therapy were surface stained with CD4-FITC- and CD8-PE-specific surface antibodies. Lymphocytes were isolated by forward and side scatter and then gated by CD3-FITC to determine the T-cell subset. The CD3-FITC-positive population was further analyzed for the expression of CD4-APC and CD8-PE to define these T-cell subsets. Results illustrate percentage of peripheral CD4+ and CD8+ lymphocytes in Patients 1–4 and 7. b PBMC collected from patients in Cohort A before and after ZA and IL-2 therapy and stained with Vγ9-FITC- and Vδ2-PE-labeled antibodies. Lymphocytes were isolated by forward and side scatter and then gated by FITC and PE to isolate Vγ9 Vδ2 T cells. Blood samples were drawn pretreatment on Day 1 (designated as Day 0 as pretreatment) and post-treatment on Day 4 of each cycle, i.e., C1D0, C1D4, C2D0, and C2D4. C Cycle, D Day